DEBRA Research and Dermaliq Join Forces for Epidermolysis Bullosa Treatment

DEBRA Research GmbH and Dermaliq Therapeutics have announced a strategic collaboration aimed at improving treatments for Epidermolysis Bullosa (EB), a rare genetic skin disorder. Their efforts will initially focus on innovative topical therapies for wound healing and itch relief, using Dermaliq's hyliQ® technology. This proprietary platform allows touchless delivery of medications to fragile skin, characteristic of EB.

EB, caused by gene mutations impacting skin integrity, leads to painful blisters and wounds from minor friction. Current treatments are limited, prompting the need for new approaches. Dermaliq's technology offers a novel method for applying treatments without damaging delicate skin.

This collaboration highlights a shared commitment to addressing medical needs in the EB community, aiming to advance new therapeutic strategies and improve patient outcomes. DEBRA has also made a strategic investment in Dermaliq, demonstrating confidence in their joint mission to enhance the quality of life for individuals with EB.